Results 271 to 280 of about 1,085,685 (349)

Conceptual Methodological Framework for Incorporating Antimicrobial Resistance Considerations in Economic Models for Pneumococcal Conjugate Vaccines. [PDF]

Infect Dis Ther
Rozenbaum MH, Tort MJ, Chapman R, Perez KK, Dillon-Murphy D, Althouse BM, Farkouh R.   +6 more
europepmc   +1 more source

Programmable Antigen‐Specific Immunity via Self‐Adjuvanting Nanovaccines Co‐Delivering Immune Modulators

Angewandte Chemie, EarlyView.
The self‐adjuvanting vaccine—comprising a covalent conjugate of antigen and adjuvant—was formulated into cationic lipid nanoparticles smaller than 100 nm to facilitate uptake by immune cells, with supplemental adjuvants incorporated to modulate immune responses.
Keita Ito, Yoshiyuki Manabe, Shino Ohshima, Masatoshi Maeki, Manabu Tokeshi, Hiroshi Inaba, Kazunori Matsuura, Kazuya Kabayama, Yoshie Kametani, Koichi Fukase   +9 more
wiley   +1 more source

Pneumococcal Vaccination of Adults in Italy: What Strategies? [PDF]

J Prev Med Hyg
Massaro E, Gabutti G.
europepmc   +1 more source

A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host [PDF]

, 2019
Chavez, Sthefany M., Feldman, Mario F., Huynh, Jeremy P., Kinsella, Rachel L., Mayer, Anne E., Stallings, Christina L.   +5 more
core   +1 more source

A Phase III Clinical Trial of Immunogenicity and Safety of Meningococcal A and C Polysaccharide Conjugate Vaccine in Infants Aged 3-5 Months. [PDF]

Vaccines (Basel)
Shi L, Zhang Z, Liu Y, Li M, Lu W, Yang Y, Zhao D, Wang B, Fang W.   +8 more
europepmc   +1 more source

Immunodeficiency in Children With Invasive Pneumococcal Disease. [PDF]

Cureus
Almesfer AM, AlSaiary MM, Alharbi FM, Alradhi SI.   +3 more
europepmc   +1 more source